WILMINGTON, Del., July 09, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), a leading Medicare Advantage company committed to affordable, high-quality care, today announced the launch of a new community-based pharmacy pilot program across New Jersey. Built in partnership with IPC Digital Health™, a division of Independent Pharmacy Cooperative (IPC), this initiative is designed to help seniors better manage their medications and stay healthier at home, supported by the local pharmacies they know and trust.
The program will be anchored by IPC’s iCare+™ Independent Pharmacy Network, which includes thousands of community-rooted pharmacies nationwide and many in New Jersey. These local pharmacies will deploy innovative care tools and virtual services that help Clover members with chronic conditions stay on track with their medications and avoid unnecessary hospital visits.
“This is more than a new program—it’s a new model for how we support our New Jersey members,” said Jamie Reynoso, CEO of Medicare Advantage at Clover Health. “By working with the pharmacists who are already embedded in our communities, we can deliver better care, deliver amazing customer experiences and support the independent businesses that keep New Jersey strong.”
Participating iCare+ pharmacies will use real-time tools, powered by Clover Assistant data and AI models, to monitor prescription fills, identify adherence gaps, and collaborate with local doctors and Clover’s care teams. The goal: make it easier for seniors to get the right medications at the right time, while keeping their care close to home.
“Clover Health understands that innovation doesn’t always mean centralization,” said Ashton Maaraba, President of IPC Digital Health. “This partnership helps New Jersey’s independent pharmacies lead the way in delivering smarter, more connected care.”
This new program is part of Clover’s broader commitment to investing in New Jersey communities, by combining modern technology, local relationships, and a belief that healthcare should feel personal again.
About Clover Health
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence and Congestive Heart Failure, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.
Visit: www.cloverhealth.com
Investor Relations:
Ryan Schmidt
This email address is being protected from spambots. You need JavaScript enabled to view it.
Press Inquiries:
This email address is being protected from spambots. You need JavaScript enabled to view it.
About IPC Digital Health™
IPC Digital Health™ is the innovation arm of the Independent Pharmacy Cooperative, the country’s largest GPO owned by independent pharmacies. Through its iCare+™ platform, IPC delivers digital health solutions that strengthen the clinical and financial future of community pharmacies. Learn more at www.myicareplus.com
Last Trade: | US$3.16 |
Daily Change: | -0.06 -1.86 |
Daily Volume: | 13,457,221 |
Market Cap: | US$1.330B |
September 25, 2025 September 16, 2025 September 09, 2025 August 05, 2025 July 29, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load